Lexicon Pharmaceuticals
LXRX
96 hedge funds and large institutions have $583M invested in Lexicon Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 33 increasing their positions, 35 reducing their positions, and 19 closing their positions.
170% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $483K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
8% more capital invested
Capital invested by funds: $540M → $583M (+$42.8M)
2.38% more ownership
Funds ownership: 81.52% → 83.9% (+2.4%)
6% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 35
10% less funds holding
Funds holding: 107 → 96 (-11)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$24.5M |
| 2 |
EP
Eversept Partners
New York
|
+$2.64M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
+$1.44M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$1.07M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$521K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4M |
| 2 |
BIG
Boothe Investment Group
Dover,
Delaware
|
-$2.04M |
| 3 |
Two Sigma Advisers
New York
|
-$1.65M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.58M |
| 5 |
Two Sigma Investments
New York
|
-$1.34M |
LXRX Hedge Fund Activity: Q3 2021 in Review
96 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2021, worth a combined $583M — up 7.9% from $540M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LXRX and 8 opened new positions — a net loss of 11 holders — while 35 trimmed existing stakes and 33 added.
The largest buyer was BVF Inc, adding an estimated $24.5M. The largest seller was Fidelity Investments, cutting an estimated $4M.
- 96 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2021, down from 107 in Q2 2021.
- Funds reported $583M of Lexicon Pharmaceuticals stock for Q3 2021, up 7.9% quarter-over-quarter.
- 8 funds opened new Lexicon Pharmaceuticals positions in Q3 2021 and 19 closed out, a net change of -11 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2021 was BVF Inc, an estimated $24.5M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2021 was Fidelity Investments, an estimated $4M sold.
Based on aggregated 13F filings for Q3 2021.